These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7395625)

  • 1. The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.
    Goldstein M; Lew JY; Sauter A; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():75-82. PubMed ID: 7395625
    [No Abstract]   [Full Text] [Related]  

  • 2. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR; Creese I
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors.
    Rosenfeld MR; Makman MH; Ahn HS; Thal LJ; Mishra RK; Katzman R
    Adv Biochem Psychopharmacol; 1980; 23():83-93. PubMed ID: 6249092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic activity of some ergot alkaloid derivatives: relationship to their chemical structure.
    Soskić V; Petrović J; Trajković D; Kidric M
    Pharmacology; 1986; 32(3):157-66. PubMed ID: 2938196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
    Goldstein M; Lew JY; Hata F; Lieberman A
    Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple receptors for dopamine.
    Kebabian JW; Calne DB
    Nature; 1979 Jan; 277(5692):93-6. PubMed ID: 215920
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical lesion and drug induced supersensitivity and subsensitivity of caudate dopamine receptors.
    Mishra RK; Wong YW; Varmuza SL; Tuff L
    Life Sci; 1978 Aug; 23(5):443-6. PubMed ID: 692267
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of some ergot alkaloids on dopamine receptors of molluscan smooth muscle.
    Ishii Y; Takayanagi I
    J Pharmacobiodyn; 1982 Sep; 5(9):748-50. PubMed ID: 7153848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine-sensitive adenylyl cyclase: a receptor mechanism for dopamine.
    Kebabian JW
    Adv Biochem Psychopharmacol; 1978; 19():131-54. PubMed ID: 29445
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine supersensitivity in the hypothalamus?
    Reid JL
    Adv Neurol; 1975; 9():73-80. PubMed ID: 167569
    [No Abstract]   [Full Text] [Related]  

  • 12. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
    Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
    Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ergot alkaloids and central monoaminergic receptors.
    Goldstein M
    J Pharmacol; 1985; 16 Suppl 3():19-24. PubMed ID: 3005775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple CNS receptor interactions of ergot alkaloids: affinity and intrinsic activity analysis in in vitro binding systems.
    U'Prichard DC
    Adv Biochem Psychopharmacol; 1980; 23():103-15. PubMed ID: 6249089
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of NMDA and MK-801 injected into the substantia nigra pars reticulata on jaw movements evoked by dopamine D1-/D2 receptor stimulation in the ventrolateral striatum: studies in freely moving rats.
    Uchida T; Lee J; Fujita S; Kiguchi M; Matsumoto M; Oi Y; Gionhaku N; Koshikawa N
    Methods Find Exp Clin Pharmacol; 2005; 27(1):31-7. PubMed ID: 15834457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of ergot compounds with dopamine receptors and endocrine functions.
    Flückiger E
    J Neural Transm Suppl; 1983; 18():189-204. PubMed ID: 6576114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.
    Spano PF; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1978; 19():155-65. PubMed ID: 358777
    [No Abstract]   [Full Text] [Related]  

  • 18. Interaction of dopaminergic ergot derivatives with cyclic nucleotide system.
    Spano PF; Saiani L; Memo M; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():95-102. PubMed ID: 6249093
    [No Abstract]   [Full Text] [Related]  

  • 19. Structural modifications of the ergopeptine molecule and their differential influence on the affinities to different receptor binding sites--a structure affinity analysis.
    Closse A; Bolliger G; Dravid A; Frick W; Hauser D; Pfäffli P; Sauter A; Tobler HJ
    Adv Biochem Psychopharmacol; 1983; 36():269-79. PubMed ID: 6305153
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells.
    Lawson CF; Mortimore RA; Schlachter SK; Smith MW
    Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):303-7. PubMed ID: 7934308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.